MedPath

Metformin

Generic Name
Metformin
Brand Names
Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
Drug Type
Small Molecule
Chemical Formula
C4H11N5
CAS Number
657-24-9
Unique Ingredient Identifier
9100L32L2N
Background

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication

Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
-
eagletribune.com
·

Promise Bio Emerges from Stealth with $8.3M Seed Investment to Transform Precision

Promise Bio announces $8.3M seed funding to develop a platform integrating epiproteomics and AI for personalized treatments and drug development.
abc.net.au
·

Remaining Bali Nine members return to Australia after 19 years in Indonesian prison

Five Bali Nine members returned to Australia after 20 years in Indonesian prisons, expressing gratitude to President Prabowo Subianto. They were provided temporary accommodation for resettlement and are now free to live in Australia.
ard.bmj.com
·

Psoriasis: epidemiology, clinical features, and quality of life

Psoriasis prevalence varies globally, with 2% affected in the USA and higher rates in the Faroe Islands. It can occur at any age, with a bimodal onset at 15-20 and 55-60 years. Type I (≤40 years) is more common and severe, linked to HLA-Cw6. Psoriasis types include plaque, guttate, flexural, erythroderma, and pustular forms, each with distinct characteristics. Psoriasis significantly impacts quality of life, with psychological stress exacerbating the condition. Treatment efficacy often focuses on physical measures, but quality of life improvements are crucial for patients.
finance.yahoo.com
·

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Zymeworks advances its R&D pipeline, focusing on novel antibody-based therapeutics for difficult-to-treat diseases, with clinical data expected by 2025. The company is progressing five drug candidates for solid tumors, including gynecological, thoracic, and digestive system cancers, ahead of schedule. Zymeworks also expands into AIID and hematology oncology, leveraging multispecific antibody therapeutics to address serious diseases with limited treatment options.
pharmaphorum.com
·

The future of patient registries: Leveraging technology for superior data and insights

Healthcare's need for real world evidence (RWE) is growing, driven by stakeholders seeking insights into drug effects. Technological advancements have improved data collection, enabling higher-quality RWE from patient registries. These registries now integrate diverse data sources and digital technologies, enhancing patient participation and data quality. Four trends—decentralised clinical trials, wearable devices, enhanced data sharing, and data linkage—are transforming registries into strategic RWE assets.

AI and Pharma: Top 10 Use Cases

AI in pharma addresses R&D costs, supply chain complexity, and data management by accelerating drug development, automating compliance, managing large datasets, and optimizing clinical trials. Swiss startup Risklick uses AI to streamline clinical trial protocols and integrate historical data. As AI evolves, stakeholders must integrate these innovations to optimize research, enhance data-driven decisions, and meet patient needs.
media.market.us
·

AI in Medical Writing Market Growing at 12.8% CAGR

The global AI in Medical Writing Market is projected to grow from USD 799.2 Million in 2023 to USD 2598.7 Million by 2033, driven by advancements in NLP and ML, government initiatives, and demand for personalized medicine. AI tools streamline clinical documentation, regulatory submissions, and scientific writing, addressing challenges like data privacy and ethical issues through evolving regulatory frameworks.

Why scientific AI needs clear lines of sight — especially for fields like drug development

Large language models pose risks in scientific research due to hallucination rates, prompting concerns among researchers. Retrieval Augmented Generation (RAG) enhances trustworthiness by grounding AI with external data sources, aiding in data provenance. Precision engineering and human oversight are crucial for reliable AI implementation, ensuring accuracy and reproducibility. The evolution of AI tools aims to augment human researchers, maintaining human centrality in decision-making while prioritizing data quality and security.
nature.com
·

Spatial heterogeneity accelerates phase-to-trigger wave transitions in frog egg extracts

Mitotic waves transition from phase waves to trigger waves in Xenopus laevis egg extracts, characterized by a shift from synchronous, fast-moving early patterns to linear, slow-moving later patterns. The transition is quantified by measuring period and wave speed, revealing a two-step process with an initial fast decay followed by a slower transition to a terminal speed. Nuclei and external driving via cytostatic-factor (CSF) extract accelerate this transition, acting as pacemakers and promoting spatial heterogeneity, respectively. The study highlights the role of spatial heterogeneity in entraining the system to the trigger wave regime, distinguishing trigger waves' stable speed from phase waves' arbitrary speed.
bakersfield.com
·

Better care for more people: Philips innovates in AI-enabled imaging and cloud-based

Philips' advanced diagnostic and treatment solutions, coupled with healthcare informatics, uniquely position the company to drive precision imaging for more patients, enhancing patient outcomes through intelligent technologies and data-driven insights.
© Copyright 2025. All Rights Reserved by MedPath